NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 886.6 DKK | +2.28% |
|
+2.36% | +27.00% |
| 25/04 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| 25/04 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
| Sales 2024 * | 287B 41.21B 3,436B | Sales 2025 * | 346B 49.58B 4,134B | Capitalization | 3,955B 567B 47,294B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 14.85B 1,238B | Net income 2025 * | 125B 17.9B 1,493B | EV / Sales 2024 * | 13.8 x |
| Net Debt 2024 * | 23.85B 3.42B 285B | Net cash position 2025 * | 348M 49.96M 4.17B | EV / Sales 2025 * | 11.4 x |
| P/E ratio 2024 * |
38.4
x | P/E ratio 2025 * |
31.6
x | Employees | 63,845 |
| Yield 2024 * |
1.33% | Yield 2025 * |
1.59% | Free-Float | 71.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More press releases
More news
| 1 day | +2.28% | ||
| 1 week | +2.36% | ||
| Current month | +0.60% | ||
| 1 month | -0.19% | ||
| 3 months | +21.12% | ||
| 6 months | +31.06% | ||
| Current year | +27.00% |
1 week
850.70
894.10
1 month
845.10898.00
Current year
688.80932.00
1 year
504.40932.00
3 years
224.55932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 19/15/19 |
Helge Lund
CHM | Chairman | 61 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 192 M€ | +13.43% | ||
| 10.45% | 5 M€ | +8.63% | ||
| 5.40% | 18 M€ | +3.79% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 886.6 | +2.28% | 2,082,169 |
| 25/24/25 | 866.8 | -1.35% | 2,439,240 |
| 24/24/24 | 878.7 | -1.41% | 1,877,505 |
| 23/24/23 | 891.3 | +1.83% | 1,866,811 |
| 22/24/22 | 875.3 | +1.05% | 2,031,675 |
Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 08:29 pm IST
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
886.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+1.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.00% | 566B | |
| +25.83% | 661B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B | |
| -11.77% | 144B |
- Stock Market
- Equities
- NOVO B Stock
